Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer reports positive clinical trial data for atopic dermatitis therapy

Pfizer reports positive clinical trial data for atopic dermatitis therapy

14th July 2016

Pfizer has announced new clinical trial results showing the effectiveness of crisaborole in the treatment of mild to moderate atopic dermatitis.

Published in the Journal of the American Academy of Dermatology, the findings from the two phase III clinical studies showed that the investigational crisaborole topical ointment delivered statistically significant results on the primary and secondary endpoints of the trials.

The ointment proved effective in the treatment of adults and children aged two and upwards versus vehicle ointment alone, with crisaborole treatment-related adverse events shown to be infrequent and moderate at worst.

Crisaborole was acquired by Pfizer as part of its takeover of Anacor Pharmaceuticals, which was completed last month. If approved, it would represent the first product to be commercialised as a result of the combination with Anacor.

Michael Corbo, chief development officer for inflammation and immunology for Pfizer Global Product Development, said: "This publication highlights the quality of the phase III clinical data with crisaborole, and we are excited to continue to work with our Anacor colleagues and regulatory authorities in our effort to bring this important medicine to patients."ADNFCR-8000103-ID-801821778-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.